Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Grifols SA Pref (GRLSbn)

Create Alert
Create Alert
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile






Delivery Method


Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
12.990 +0.070    +0.54%
24/02 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Spain
ISIN:  ES0171996095 
  • Volume: 139,745
  • Bid/Ask: 12.990 / 12.990
  • Day's Range: 12.910 - 13.050
Grifols Pref 12.990 +0.070 +0.54%
IndustryBiotechnology & Drugs


Equity Type


Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Contact Information

Phone +34-935-710000
Fax 935-710267

Top Executives

Name Age Since Title
Victor Grifols Roura - 2017 Non-Executive Chairman of the Board
Ramon Riera Roca - 2018 Director
Tomas Daga Gelabert - 2016 Vice Secretary, Director
Thomas Glanzmann 62 2017 Non-Executive Vice Chairman of the Board
Alfredo Arroyo Guerra - 2014 Chief Financial Officer
Nuria Pascual Lapena - 2019 VP Corporate Treasury & Investor Relations
Vicente Blanquer Torre - 2014 Vice President - Quality & Regulatory affairs
Raimon Grifols Roura - 2017 Co-Chief Executive Officer, Executive Director
Nuria Martin Barnes - 2015 Non-Member Secretary of the Board of Directors
Mateo Borras Humbert - 2014 Chief Human Resource Officer
Alberto Grifols Roura - 2019 President - Commercial Operations Management
Miguel Pascual Montblanch - 2019 President, Commercial Operations Management
Steven F. Mayer 59 2016 Independent Director
David Ian Bell 67 2017 General Counsel and Chief Innovation Officer
Joel Abelson - 2018 President, Bioscience Commercial Division
Belen Villalonga Morenes - 2013 Independent Director
Marla Elizabeth Salmon - 2014 Independent Director
Lafmin Morgan 55 2018 Chief Commercial Officer
Carina Szpilka Lazaro 52 2015 Independent Director
Inigo Sanchez Asiain Mardones - 2017 Lead Independent Director
Victor Grifols Deu - 2017 Co-Chief Executive Officer, Executive Director
Enriqueta Felip Font - 2019 Independent Director
Matt Murawski - 2019 VP Innovation Operations & Analytics
Maria Teresa Rione - - Vice President - Corporate Communications
Javier Sueiras Gil - 2018 Chief IT Officer
Luis Twose Garcon - 2018 Managing Director - Laboratorios Grifols
Daniel Fleta Coit - 2019 Chief Industrial Officer
Albert Grifols Coma-Cros - - President, Grifols Worldwide Operations
James Costos 57 2020 Independent Director
Chris Healey - 2020 President, Na Corporate Affairs
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

GRLSbn Comments

Write your thoughts about Grifols SA Pref
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email